nodes	percent_of_prediction	percent_of_DWPC	metapath
Amoxapine—ORM1—Vismodegib—skin cancer	0.337	0.512	CbGbCtD
Amoxapine—ORM1—Vemurafenib—skin cancer	0.266	0.404	CbGbCtD
Amoxapine—CYP2D6—Vemurafenib—skin cancer	0.0552	0.0839	CbGbCtD
Amoxapine—HRH1—nose—skin cancer	0.00666	0.0823	CbGeAlD
Amoxapine—DRD1—nerve—skin cancer	0.00409	0.0506	CbGeAlD
Amoxapine—HTR3A—nerve—skin cancer	0.00395	0.0488	CbGeAlD
Amoxapine—SLC6A3—nerve—skin cancer	0.00329	0.0406	CbGeAlD
Amoxapine—SLC6A2—nerve—skin cancer	0.00265	0.0328	CbGeAlD
Amoxapine—HTR2A—hindlimb—skin cancer	0.00262	0.0324	CbGeAlD
Amoxapine—HTR1B—blood vessel—skin cancer	0.0026	0.0322	CbGeAlD
Amoxapine—HTR7—nerve—skin cancer	0.00255	0.0316	CbGeAlD
Amoxapine—DRD2—nerve—skin cancer	0.00242	0.0299	CbGeAlD
Amoxapine—HTR2A—appendage—skin cancer	0.00225	0.0278	CbGeAlD
Amoxapine—HTR7—endothelium—skin cancer	0.00218	0.0269	CbGeAlD
Amoxapine—HTR7—blood vessel—skin cancer	0.00201	0.0248	CbGeAlD
Amoxapine—Purpura—Imiquimod—skin cancer	0.00189	0.00927	CcSEcCtD
Amoxapine—Cerebrovascular accident—Imiquimod—skin cancer	0.00186	0.00912	CcSEcCtD
Amoxapine—Petechiae—Temozolomide—skin cancer	0.00182	0.00897	CcSEcCtD
Amoxapine—Eosinophilia—Vemurafenib—skin cancer	0.00182	0.00897	CcSEcCtD
Amoxapine—Menstruation irregular—Docetaxel—skin cancer	0.0018	0.00886	CcSEcCtD
Amoxapine—Disturbance in attention—Temozolomide—skin cancer	0.00173	0.00852	CcSEcCtD
Amoxapine—Urinary retention—Imiquimod—skin cancer	0.00173	0.0085	CcSEcCtD
Amoxapine—Tingling sensation—Fluorouracil—skin cancer	0.00172	0.00846	CcSEcCtD
Amoxapine—Lacrimation—Docetaxel—skin cancer	0.0017	0.00834	CcSEcCtD
Amoxapine—Numbness—Fluorouracil—skin cancer	0.00167	0.0082	CcSEcCtD
Amoxapine—Sensory loss—Fluorouracil—skin cancer	0.0016	0.00785	CcSEcCtD
Amoxapine—HTR2A—nerve—skin cancer	0.00159	0.0197	CbGeAlD
Amoxapine—Coordination abnormal—Temozolomide—skin cancer	0.00153	0.00751	CcSEcCtD
Amoxapine—Lacrimation increased—Fluorouracil—skin cancer	0.0015	0.00738	CcSEcCtD
Amoxapine—Dyspepsia—Vismodegib—skin cancer	0.00149	0.00734	CcSEcCtD
Amoxapine—Decreased appetite—Vismodegib—skin cancer	0.00147	0.00725	CcSEcCtD
Amoxapine—Fatigue—Vismodegib—skin cancer	0.00146	0.00719	CcSEcCtD
Amoxapine—Constipation—Vismodegib—skin cancer	0.00145	0.00713	CcSEcCtD
Amoxapine—Erectile dysfunction—Imiquimod—skin cancer	0.00145	0.00711	CcSEcCtD
Amoxapine—Disorientation—Bleomycin—skin cancer	0.00144	0.0071	CcSEcCtD
Amoxapine—HTR7—neck—skin cancer	0.00144	0.0178	CbGeAlD
Amoxapine—Gastrointestinal pain—Vismodegib—skin cancer	0.00139	0.00682	CcSEcCtD
Amoxapine—Acute coronary syndrome—Imiquimod—skin cancer	0.00138	0.00679	CcSEcCtD
Amoxapine—Myocardial infarction—Imiquimod—skin cancer	0.00137	0.00675	CcSEcCtD
Amoxapine—HTR2A—endothelium—skin cancer	0.00136	0.0168	CbGeAlD
Amoxapine—DRD3—head—skin cancer	0.00135	0.0168	CbGeAlD
Amoxapine—Abdominal pain—Vismodegib—skin cancer	0.00134	0.00659	CcSEcCtD
Amoxapine—Cerebrovascular accident—Bleomycin—skin cancer	0.00132	0.00648	CcSEcCtD
Amoxapine—HTR6—head—skin cancer	0.0013	0.0161	CbGeAlD
Amoxapine—Alopecia—Vemurafenib—skin cancer	0.0013	0.00641	CcSEcCtD
Amoxapine—Mental disability—Temozolomide—skin cancer	0.0013	0.0064	CcSEcCtD
Amoxapine—Dysgeusia—Vemurafenib—skin cancer	0.00126	0.00618	CcSEcCtD
Amoxapine—HTR2A—blood vessel—skin cancer	0.00125	0.0155	CbGeAlD
Amoxapine—Vascular purpura—Temozolomide—skin cancer	0.00122	0.00599	CcSEcCtD
Amoxapine—Asthenia—Vismodegib—skin cancer	0.00122	0.00598	CcSEcCtD
Amoxapine—Pruritus—Vismodegib—skin cancer	0.0012	0.0059	CcSEcCtD
Amoxapine—Nasal congestion—Temozolomide—skin cancer	0.0012	0.00588	CcSEcCtD
Amoxapine—Tinnitus—Imiquimod—skin cancer	0.00117	0.00576	CcSEcCtD
Amoxapine—Diarrhoea—Vismodegib—skin cancer	0.00116	0.0057	CcSEcCtD
Amoxapine—Purpura—Temozolomide—skin cancer	0.00113	0.00556	CcSEcCtD
Amoxapine—Disorientation—Fluorouracil—skin cancer	0.00112	0.00552	CcSEcCtD
Amoxapine—Alopecia—Imiquimod—skin cancer	0.00111	0.00546	CcSEcCtD
Amoxapine—HTR2B—skin of body—skin cancer	0.00108	0.0134	CbGeAlD
Amoxapine—Lacrimation increased—Docetaxel—skin cancer	0.00108	0.00532	CcSEcCtD
Amoxapine—HRH1—nipple—skin cancer	0.00108	0.0134	CbGeAlD
Amoxapine—Vomiting—Vismodegib—skin cancer	0.00108	0.0053	CcSEcCtD
Amoxapine—Rash—Vismodegib—skin cancer	0.00107	0.00526	CcSEcCtD
Amoxapine—Dermatitis—Vismodegib—skin cancer	0.00107	0.00525	CcSEcCtD
Amoxapine—ADRA2A—nipple—skin cancer	0.00106	0.0132	CbGeAlD
Amoxapine—HTR7—connective tissue—skin cancer	0.00103	0.0127	CbGeAlD
Amoxapine—Ataxia—Temozolomide—skin cancer	0.00102	0.00504	CcSEcCtD
Amoxapine—Nausea—Vismodegib—skin cancer	0.00101	0.00495	CcSEcCtD
Amoxapine—Agitation—Imiquimod—skin cancer	0.00101	0.00495	CcSEcCtD
Amoxapine—ORM1—female reproductive system—skin cancer	0.001	0.0124	CbGeAlD
Amoxapine—Syncope—Imiquimod—skin cancer	0.000982	0.00483	CcSEcCtD
Amoxapine—Acute coronary syndrome—Bleomycin—skin cancer	0.000981	0.00482	CcSEcCtD
Amoxapine—Hypotension—Vemurafenib—skin cancer	0.000979	0.00481	CcSEcCtD
Amoxapine—HTR7—epithelium—skin cancer	0.000977	0.0121	CbGeAlD
Amoxapine—Myocardial infarction—Bleomycin—skin cancer	0.000976	0.0048	CcSEcCtD
Amoxapine—Stomatitis—Bleomycin—skin cancer	0.00097	0.00477	CcSEcCtD
Amoxapine—DRD1—head—skin cancer	0.00097	0.012	CbGeAlD
Amoxapine—Palpitations—Imiquimod—skin cancer	0.000967	0.00476	CcSEcCtD
Amoxapine—Loss of consciousness—Imiquimod—skin cancer	0.000962	0.00473	CcSEcCtD
Amoxapine—Convulsion—Imiquimod—skin cancer	0.000949	0.00466	CcSEcCtD
Amoxapine—Hypertension—Imiquimod—skin cancer	0.000945	0.00465	CcSEcCtD
Amoxapine—Ataxia—Fluorouracil—skin cancer	0.000944	0.00464	CcSEcCtD
Amoxapine—ADRA1A—epithelium—skin cancer	0.000942	0.0117	CbGeAlD
Amoxapine—HTR1B—female reproductive system—skin cancer	0.000941	0.0116	CbGeAlD
Amoxapine—HTR3A—head—skin cancer	0.000937	0.0116	CbGeAlD
Amoxapine—Dry mouth—Imiquimod—skin cancer	0.000912	0.00448	CcSEcCtD
Amoxapine—Decreased appetite—Vemurafenib—skin cancer	0.000911	0.00448	CcSEcCtD
Amoxapine—Stomatitis—Dactinomycin—skin cancer	0.000905	0.00445	CcSEcCtD
Amoxapine—Fatigue—Vemurafenib—skin cancer	0.000903	0.00444	CcSEcCtD
Amoxapine—HTR2C—female reproductive system—skin cancer	0.000902	0.0112	CbGeAlD
Amoxapine—Constipation—Vemurafenib—skin cancer	0.000896	0.0044	CcSEcCtD
Amoxapine—HTR2A—neck—skin cancer	0.000895	0.0111	CbGeAlD
Amoxapine—Oedema—Imiquimod—skin cancer	0.000893	0.00439	CcSEcCtD
Amoxapine—Hypoaesthesia—Bleomycin—skin cancer	0.000889	0.00437	CcSEcCtD
Amoxapine—Shock—Imiquimod—skin cancer	0.000879	0.00432	CcSEcCtD
Amoxapine—Tachycardia—Imiquimod—skin cancer	0.000872	0.00429	CcSEcCtD
Amoxapine—Pollakiuria—Temozolomide—skin cancer	0.00087	0.00428	CcSEcCtD
Amoxapine—Erectile dysfunction—Temozolomide—skin cancer	0.000867	0.00426	CcSEcCtD
Amoxapine—Agranulocytosis—Dactinomycin—skin cancer	0.000866	0.00426	CcSEcCtD
Amoxapine—Eosinophilia—Fluorouracil—skin cancer	0.000859	0.00422	CcSEcCtD
Amoxapine—Weight increased—Temozolomide—skin cancer	0.000857	0.00421	CcSEcCtD
Amoxapine—SLC6A4—female reproductive system—skin cancer	0.000855	0.0106	CbGeAlD
Amoxapine—Anorexia—Imiquimod—skin cancer	0.000852	0.00419	CcSEcCtD
Amoxapine—CHRM1—female reproductive system—skin cancer	0.000852	0.0105	CbGeAlD
Amoxapine—HTR2B—female reproductive system—skin cancer	0.000847	0.0105	CbGeAlD
Amoxapine—Hepatitis—Dactinomycin—skin cancer	0.000833	0.0041	CcSEcCtD
Amoxapine—Body temperature increased—Vemurafenib—skin cancer	0.000828	0.00407	CcSEcCtD
Amoxapine—Stomatitis—Temozolomide—skin cancer	0.000818	0.00402	CcSEcCtD
Amoxapine—Insomnia—Imiquimod—skin cancer	0.000808	0.00397	CcSEcCtD
Amoxapine—Paraesthesia—Imiquimod—skin cancer	0.000802	0.00394	CcSEcCtD
Amoxapine—Somnolence—Imiquimod—skin cancer	0.000794	0.0039	CcSEcCtD
Amoxapine—Alopecia—Bleomycin—skin cancer	0.000789	0.00388	CcSEcCtD
Amoxapine—Dyspepsia—Imiquimod—skin cancer	0.000786	0.00387	CcSEcCtD
Amoxapine—HTR1B—head—skin cancer	0.000786	0.00972	CbGeAlD
Amoxapine—GABRA1—head—skin cancer	0.000786	0.00972	CbGeAlD
Amoxapine—SLC6A3—head—skin cancer	0.000779	0.00964	CbGeAlD
Amoxapine—Decreased appetite—Imiquimod—skin cancer	0.000777	0.00382	CcSEcCtD
Amoxapine—Fatigue—Imiquimod—skin cancer	0.00077	0.00379	CcSEcCtD
Amoxapine—HRH1—connective tissue—skin cancer	0.000768	0.0095	CbGeAlD
Amoxapine—Atrial fibrillation—Docetaxel—skin cancer	0.000764	0.00376	CcSEcCtD
Amoxapine—Acute coronary syndrome—Fluorouracil—skin cancer	0.000763	0.00375	CcSEcCtD
Amoxapine—Myocardial infarction—Fluorouracil—skin cancer	0.000758	0.00373	CcSEcCtD
Amoxapine—ADRA2A—connective tissue—skin cancer	0.000754	0.00933	CbGeAlD
Amoxapine—Stomatitis—Fluorouracil—skin cancer	0.000754	0.00371	CcSEcCtD
Amoxapine—Hepatitis—Temozolomide—skin cancer	0.000754	0.0037	CcSEcCtD
Amoxapine—HTR2C—head—skin cancer	0.000753	0.00932	CbGeAlD
Amoxapine—SLC6A2—female reproductive system—skin cancer	0.000753	0.00931	CbGeAlD
Amoxapine—Asthenia—Vemurafenib—skin cancer	0.000752	0.0037	CcSEcCtD
Amoxapine—Hallucination—Temozolomide—skin cancer	0.00075	0.00369	CcSEcCtD
Amoxapine—Hypoaesthesia—Temozolomide—skin cancer	0.00075	0.00369	CcSEcCtD
Amoxapine—Pruritus—Vemurafenib—skin cancer	0.000741	0.00364	CcSEcCtD
Amoxapine—Alopecia—Dactinomycin—skin cancer	0.000736	0.00362	CcSEcCtD
Amoxapine—Feeling abnormal—Imiquimod—skin cancer	0.000736	0.00362	CcSEcCtD
Amoxapine—Gastrointestinal pain—Imiquimod—skin cancer	0.000731	0.00359	CcSEcCtD
Amoxapine—HRH1—epithelium—skin cancer	0.000729	0.00902	CbGeAlD
Amoxapine—ADRA1A—lymphoid tissue—skin cancer	0.000725	0.00897	CbGeAlD
Amoxapine—HTR7—female reproductive system—skin cancer	0.000725	0.00897	CbGeAlD
Amoxapine—Agranulocytosis—Fluorouracil—skin cancer	0.000722	0.00355	CcSEcCtD
Amoxapine—Diarrhoea—Vemurafenib—skin cancer	0.000717	0.00352	CcSEcCtD
Amoxapine—SLC6A4—head—skin cancer	0.000714	0.00883	CbGeAlD
Amoxapine—CHRM1—head—skin cancer	0.000711	0.0088	CbGeAlD
Amoxapine—Urticaria—Imiquimod—skin cancer	0.00071	0.00349	CcSEcCtD
Amoxapine—HTR2B—head—skin cancer	0.000708	0.00875	CbGeAlD
Amoxapine—Body temperature increased—Imiquimod—skin cancer	0.000706	0.00347	CcSEcCtD
Amoxapine—Abdominal pain—Imiquimod—skin cancer	0.000706	0.00347	CcSEcCtD
Amoxapine—Tinnitus—Temozolomide—skin cancer	0.000703	0.00345	CcSEcCtD
Amoxapine—Leukopenia—Bleomycin—skin cancer	0.000696	0.00342	CcSEcCtD
Amoxapine—Dizziness—Vemurafenib—skin cancer	0.000693	0.00341	CcSEcCtD
Amoxapine—Hypoaesthesia—Fluorouracil—skin cancer	0.000691	0.0034	CcSEcCtD
Amoxapine—Ataxia—Docetaxel—skin cancer	0.000681	0.00335	CcSEcCtD
Amoxapine—Vomiting—Vemurafenib—skin cancer	0.000666	0.00327	CcSEcCtD
Amoxapine—Alopecia—Temozolomide—skin cancer	0.000666	0.00327	CcSEcCtD
Amoxapine—Rash—Vemurafenib—skin cancer	0.000661	0.00325	CcSEcCtD
Amoxapine—Dermatitis—Vemurafenib—skin cancer	0.00066	0.00324	CcSEcCtD
Amoxapine—Headache—Vemurafenib—skin cancer	0.000656	0.00323	CcSEcCtD
Amoxapine—Leukopenia—Dactinomycin—skin cancer	0.000649	0.00319	CcSEcCtD
Amoxapine—Dysgeusia—Temozolomide—skin cancer	0.000642	0.00316	CcSEcCtD
Amoxapine—HTR2A—connective tissue—skin cancer	0.000641	0.00793	CbGeAlD
Amoxapine—Asthenia—Imiquimod—skin cancer	0.000641	0.00315	CcSEcCtD
Amoxapine—Confusional state—Bleomycin—skin cancer	0.00064	0.00315	CcSEcCtD
Amoxapine—Oedema—Bleomycin—skin cancer	0.000635	0.00312	CcSEcCtD
Amoxapine—HTR1A—head—skin cancer	0.000634	0.00784	CbGeAlD
Amoxapine—HRH1—mammalian vulva—skin cancer	0.000632	0.00782	CbGeAlD
Amoxapine—Pruritus—Imiquimod—skin cancer	0.000632	0.00311	CcSEcCtD
Amoxapine—SLC6A2—head—skin cancer	0.000629	0.00778	CbGeAlD
Amoxapine—Nausea—Vemurafenib—skin cancer	0.000622	0.00306	CcSEcCtD
Amoxapine—Thrombocytopenia—Bleomycin—skin cancer	0.000621	0.00306	CcSEcCtD
Amoxapine—ADRA2A—mammalian vulva—skin cancer	0.000621	0.00768	CbGeAlD
Amoxapine—Vision blurred—Temozolomide—skin cancer	0.000618	0.00304	CcSEcCtD
Amoxapine—Tremor—Temozolomide—skin cancer	0.000615	0.00302	CcSEcCtD
Amoxapine—Alopecia—Fluorouracil—skin cancer	0.000614	0.00302	CcSEcCtD
Amoxapine—Diarrhoea—Imiquimod—skin cancer	0.000611	0.00301	CcSEcCtD
Amoxapine—HTR2A—epithelium—skin cancer	0.000609	0.00753	CbGeAlD
Amoxapine—HTR7—head—skin cancer	0.000606	0.0075	CbGeAlD
Amoxapine—Anorexia—Bleomycin—skin cancer	0.000605	0.00297	CcSEcCtD
Amoxapine—Agitation—Temozolomide—skin cancer	0.000603	0.00296	CcSEcCtD
Amoxapine—Hypotension—Bleomycin—skin cancer	0.000593	0.00292	CcSEcCtD
Amoxapine—Oedema—Dactinomycin—skin cancer	0.000592	0.00291	CcSEcCtD
Amoxapine—Dizziness—Imiquimod—skin cancer	0.000591	0.0029	CcSEcCtD
Amoxapine—Leukopenia—Temozolomide—skin cancer	0.000587	0.00289	CcSEcCtD
Amoxapine—ORM1—lymph node—skin cancer	0.000587	0.00726	CbGeAlD
Amoxapine—ADRA1A—head—skin cancer	0.000585	0.00723	CbGeAlD
Amoxapine—Palpitations—Temozolomide—skin cancer	0.00058	0.00285	CcSEcCtD
Amoxapine—Thrombocytopenia—Dactinomycin—skin cancer	0.00058	0.00285	CcSEcCtD
Amoxapine—DRD2—head—skin cancer	0.000573	0.00709	CbGeAlD
Amoxapine—Paraesthesia—Bleomycin—skin cancer	0.00057	0.0028	CcSEcCtD
Amoxapine—Weight increased—Docetaxel—skin cancer	0.00057	0.0028	CcSEcCtD
Amoxapine—Vision blurred—Fluorouracil—skin cancer	0.00057	0.0028	CcSEcCtD
Amoxapine—Convulsion—Temozolomide—skin cancer	0.000568	0.00279	CcSEcCtD
Amoxapine—Vomiting—Imiquimod—skin cancer	0.000568	0.00279	CcSEcCtD
Amoxapine—Hypertension—Temozolomide—skin cancer	0.000566	0.00278	CcSEcCtD
Amoxapine—Anorexia—Dactinomycin—skin cancer	0.000564	0.00277	CcSEcCtD
Amoxapine—Rash—Imiquimod—skin cancer	0.000563	0.00277	CcSEcCtD
Amoxapine—Dermatitis—Imiquimod—skin cancer	0.000563	0.00277	CcSEcCtD
Amoxapine—Headache—Imiquimod—skin cancer	0.00056	0.00275	CcSEcCtD
Amoxapine—Decreased appetite—Bleomycin—skin cancer	0.000552	0.00271	CcSEcCtD
Amoxapine—Acute coronary syndrome—Docetaxel—skin cancer	0.00055	0.00271	CcSEcCtD
Amoxapine—Myocardial infarction—Docetaxel—skin cancer	0.000547	0.00269	CcSEcCtD
Amoxapine—Dry mouth—Temozolomide—skin cancer	0.000546	0.00269	CcSEcCtD
Amoxapine—Stomatitis—Docetaxel—skin cancer	0.000544	0.00268	CcSEcCtD
Amoxapine—Jaundice—Docetaxel—skin cancer	0.000544	0.00268	CcSEcCtD
Amoxapine—HRH1—female reproductive system—skin cancer	0.000542	0.0067	CbGeAlD
Amoxapine—Leukopenia—Fluorouracil—skin cancer	0.000541	0.00266	CcSEcCtD
Amoxapine—Confusional state—Temozolomide—skin cancer	0.00054	0.00265	CcSEcCtD
Amoxapine—Oedema—Temozolomide—skin cancer	0.000535	0.00263	CcSEcCtD
Amoxapine—ADRA2A—female reproductive system—skin cancer	0.000532	0.00658	CbGeAlD
Amoxapine—Nausea—Imiquimod—skin cancer	0.000531	0.00261	CcSEcCtD
Amoxapine—Thrombocytopenia—Temozolomide—skin cancer	0.000524	0.00258	CcSEcCtD
Amoxapine—Convulsion—Fluorouracil—skin cancer	0.000524	0.00257	CcSEcCtD
Amoxapine—Feeling abnormal—Bleomycin—skin cancer	0.000523	0.00257	CcSEcCtD
Amoxapine—Agranulocytosis—Docetaxel—skin cancer	0.000521	0.00256	CcSEcCtD
Amoxapine—Decreased appetite—Dactinomycin—skin cancer	0.000515	0.00253	CcSEcCtD
Amoxapine—Fatigue—Dactinomycin—skin cancer	0.00051	0.00251	CcSEcCtD
Amoxapine—Anorexia—Temozolomide—skin cancer	0.00051	0.00251	CcSEcCtD
Amoxapine—Urticaria—Bleomycin—skin cancer	0.000504	0.00248	CcSEcCtD
Amoxapine—Body temperature increased—Bleomycin—skin cancer	0.000502	0.00247	CcSEcCtD
Amoxapine—Hepatitis—Docetaxel—skin cancer	0.000501	0.00246	CcSEcCtD
Amoxapine—Hypoaesthesia—Docetaxel—skin cancer	0.000499	0.00245	CcSEcCtD
Amoxapine—Confusional state—Fluorouracil—skin cancer	0.000497	0.00245	CcSEcCtD
Amoxapine—HTR2B—lymph node—skin cancer	0.000496	0.00613	CbGeAlD
Amoxapine—Oedema—Fluorouracil—skin cancer	0.000493	0.00243	CcSEcCtD
Amoxapine—Feeling abnormal—Dactinomycin—skin cancer	0.000488	0.0024	CcSEcCtD
Amoxapine—Insomnia—Temozolomide—skin cancer	0.000484	0.00238	CcSEcCtD
Amoxapine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000484	0.00238	CcSEcCtD
Amoxapine—Thrombocytopenia—Fluorouracil—skin cancer	0.000483	0.00237	CcSEcCtD
Amoxapine—Tachycardia—Fluorouracil—skin cancer	0.000481	0.00237	CcSEcCtD
Amoxapine—Paraesthesia—Temozolomide—skin cancer	0.000481	0.00236	CcSEcCtD
Amoxapine—Somnolence—Temozolomide—skin cancer	0.000476	0.00234	CcSEcCtD
Amoxapine—Dyspepsia—Temozolomide—skin cancer	0.000471	0.00232	CcSEcCtD
Amoxapine—Anorexia—Fluorouracil—skin cancer	0.00047	0.00231	CcSEcCtD
Amoxapine—Abdominal pain—Dactinomycin—skin cancer	0.000468	0.0023	CcSEcCtD
Amoxapine—Body temperature increased—Dactinomycin—skin cancer	0.000468	0.0023	CcSEcCtD
Amoxapine—Decreased appetite—Temozolomide—skin cancer	0.000465	0.00229	CcSEcCtD
Amoxapine—Fatigue—Temozolomide—skin cancer	0.000462	0.00227	CcSEcCtD
Amoxapine—Hypotension—Fluorouracil—skin cancer	0.000461	0.00227	CcSEcCtD
Amoxapine—Constipation—Temozolomide—skin cancer	0.000458	0.00225	CcSEcCtD
Amoxapine—Asthenia—Bleomycin—skin cancer	0.000455	0.00224	CcSEcCtD
Amoxapine—HRH1—head—skin cancer	0.000453	0.0056	CbGeAlD
Amoxapine—HTR2A—female reproductive system—skin cancer	0.000452	0.0056	CbGeAlD
Amoxapine—Pruritus—Bleomycin—skin cancer	0.000449	0.00221	CcSEcCtD
Amoxapine—Insomnia—Fluorouracil—skin cancer	0.000446	0.00219	CcSEcCtD
Amoxapine—ADRA2A—head—skin cancer	0.000444	0.0055	CbGeAlD
Amoxapine—Paraesthesia—Fluorouracil—skin cancer	0.000443	0.00218	CcSEcCtD
Amoxapine—Alopecia—Docetaxel—skin cancer	0.000443	0.00218	CcSEcCtD
Amoxapine—Feeling abnormal—Temozolomide—skin cancer	0.000441	0.00217	CcSEcCtD
Amoxapine—SLC6A2—lymph node—skin cancer	0.00044	0.00545	CbGeAlD
Amoxapine—Somnolence—Fluorouracil—skin cancer	0.000439	0.00216	CcSEcCtD
Amoxapine—Gastrointestinal pain—Temozolomide—skin cancer	0.000438	0.00215	CcSEcCtD
Amoxapine—Dyspepsia—Fluorouracil—skin cancer	0.000434	0.00213	CcSEcCtD
Amoxapine—Decreased appetite—Fluorouracil—skin cancer	0.000429	0.00211	CcSEcCtD
Amoxapine—Dysgeusia—Docetaxel—skin cancer	0.000427	0.0021	CcSEcCtD
Amoxapine—Urticaria—Temozolomide—skin cancer	0.000425	0.00209	CcSEcCtD
Amoxapine—Asthenia—Dactinomycin—skin cancer	0.000425	0.00209	CcSEcCtD
Amoxapine—Body temperature increased—Temozolomide—skin cancer	0.000423	0.00208	CcSEcCtD
Amoxapine—Abdominal pain—Temozolomide—skin cancer	0.000423	0.00208	CcSEcCtD
Amoxapine—CYP2D6—female reproductive system—skin cancer	0.000412	0.0051	CbGeAlD
Amoxapine—Feeling abnormal—Fluorouracil—skin cancer	0.000407	0.002	CcSEcCtD
Amoxapine—Diarrhoea—Dactinomycin—skin cancer	0.000405	0.00199	CcSEcCtD
Amoxapine—Vomiting—Bleomycin—skin cancer	0.000404	0.00198	CcSEcCtD
Amoxapine—Rash—Bleomycin—skin cancer	0.0004	0.00197	CcSEcCtD
Amoxapine—Dermatitis—Bleomycin—skin cancer	0.0004	0.00197	CcSEcCtD
Amoxapine—Urticaria—Fluorouracil—skin cancer	0.000392	0.00193	CcSEcCtD
Amoxapine—Syncope—Docetaxel—skin cancer	0.000391	0.00192	CcSEcCtD
Amoxapine—Leukopenia—Docetaxel—skin cancer	0.000391	0.00192	CcSEcCtD
Amoxapine—Body temperature increased—Fluorouracil—skin cancer	0.00039	0.00192	CcSEcCtD
Amoxapine—Palpitations—Docetaxel—skin cancer	0.000386	0.0019	CcSEcCtD
Amoxapine—Asthenia—Temozolomide—skin cancer	0.000384	0.00189	CcSEcCtD
Amoxapine—Loss of consciousness—Docetaxel—skin cancer	0.000383	0.00189	CcSEcCtD
Amoxapine—Pruritus—Temozolomide—skin cancer	0.000379	0.00186	CcSEcCtD
Amoxapine—Convulsion—Docetaxel—skin cancer	0.000378	0.00186	CcSEcCtD
Amoxapine—HTR2A—head—skin cancer	0.000378	0.00467	CbGeAlD
Amoxapine—Nausea—Bleomycin—skin cancer	0.000377	0.00185	CcSEcCtD
Amoxapine—Hypertension—Docetaxel—skin cancer	0.000377	0.00185	CcSEcCtD
Amoxapine—Vomiting—Dactinomycin—skin cancer	0.000376	0.00185	CcSEcCtD
Amoxapine—Rash—Dactinomycin—skin cancer	0.000373	0.00183	CcSEcCtD
Amoxapine—Diarrhoea—Temozolomide—skin cancer	0.000366	0.0018	CcSEcCtD
Amoxapine—Dry mouth—Docetaxel—skin cancer	0.000363	0.00179	CcSEcCtD
Amoxapine—Confusional state—Docetaxel—skin cancer	0.000359	0.00176	CcSEcCtD
Amoxapine—Oedema—Docetaxel—skin cancer	0.000356	0.00175	CcSEcCtD
Amoxapine—Dizziness—Temozolomide—skin cancer	0.000354	0.00174	CcSEcCtD
Amoxapine—Nausea—Dactinomycin—skin cancer	0.000352	0.00173	CcSEcCtD
Amoxapine—Shock—Docetaxel—skin cancer	0.00035	0.00172	CcSEcCtD
Amoxapine—Pruritus—Fluorouracil—skin cancer	0.000349	0.00172	CcSEcCtD
Amoxapine—Thrombocytopenia—Docetaxel—skin cancer	0.000349	0.00171	CcSEcCtD
Amoxapine—Tachycardia—Docetaxel—skin cancer	0.000348	0.00171	CcSEcCtD
Amoxapine—CYP2D6—head—skin cancer	0.000344	0.00426	CbGeAlD
Amoxapine—Vomiting—Temozolomide—skin cancer	0.00034	0.00167	CcSEcCtD
Amoxapine—Anorexia—Docetaxel—skin cancer	0.000339	0.00167	CcSEcCtD
Amoxapine—Rash—Temozolomide—skin cancer	0.000338	0.00166	CcSEcCtD
Amoxapine—Diarrhoea—Fluorouracil—skin cancer	0.000338	0.00166	CcSEcCtD
Amoxapine—Dermatitis—Temozolomide—skin cancer	0.000337	0.00166	CcSEcCtD
Amoxapine—Headache—Temozolomide—skin cancer	0.000335	0.00165	CcSEcCtD
Amoxapine—Hypotension—Docetaxel—skin cancer	0.000333	0.00164	CcSEcCtD
Amoxapine—Dizziness—Fluorouracil—skin cancer	0.000326	0.0016	CcSEcCtD
Amoxapine—Insomnia—Docetaxel—skin cancer	0.000322	0.00158	CcSEcCtD
Amoxapine—Paraesthesia—Docetaxel—skin cancer	0.00032	0.00157	CcSEcCtD
Amoxapine—Nausea—Temozolomide—skin cancer	0.000318	0.00156	CcSEcCtD
Amoxapine—HRH1—lymph node—skin cancer	0.000317	0.00392	CbGeAlD
Amoxapine—Somnolence—Docetaxel—skin cancer	0.000317	0.00156	CcSEcCtD
Amoxapine—Vomiting—Fluorouracil—skin cancer	0.000314	0.00154	CcSEcCtD
Amoxapine—Dyspepsia—Docetaxel—skin cancer	0.000313	0.00154	CcSEcCtD
Amoxapine—ADRA2A—lymph node—skin cancer	0.000311	0.00385	CbGeAlD
Amoxapine—Rash—Fluorouracil—skin cancer	0.000311	0.00153	CcSEcCtD
Amoxapine—Dermatitis—Fluorouracil—skin cancer	0.000311	0.00153	CcSEcCtD
Amoxapine—Decreased appetite—Docetaxel—skin cancer	0.00031	0.00152	CcSEcCtD
Amoxapine—Headache—Fluorouracil—skin cancer	0.000309	0.00152	CcSEcCtD
Amoxapine—Fatigue—Docetaxel—skin cancer	0.000307	0.00151	CcSEcCtD
Amoxapine—Constipation—Docetaxel—skin cancer	0.000304	0.0015	CcSEcCtD
Amoxapine—Feeling abnormal—Docetaxel—skin cancer	0.000293	0.00144	CcSEcCtD
Amoxapine—Nausea—Fluorouracil—skin cancer	0.000293	0.00144	CcSEcCtD
Amoxapine—Gastrointestinal pain—Docetaxel—skin cancer	0.000291	0.00143	CcSEcCtD
Amoxapine—Abdominal pain—Docetaxel—skin cancer	0.000281	0.00138	CcSEcCtD
Amoxapine—Body temperature increased—Docetaxel—skin cancer	0.000281	0.00138	CcSEcCtD
Amoxapine—Asthenia—Docetaxel—skin cancer	0.000255	0.00126	CcSEcCtD
Amoxapine—Pruritus—Docetaxel—skin cancer	0.000252	0.00124	CcSEcCtD
Amoxapine—Diarrhoea—Docetaxel—skin cancer	0.000244	0.0012	CcSEcCtD
Amoxapine—Dizziness—Docetaxel—skin cancer	0.000235	0.00116	CcSEcCtD
Amoxapine—Vomiting—Docetaxel—skin cancer	0.000226	0.00111	CcSEcCtD
Amoxapine—Rash—Docetaxel—skin cancer	0.000225	0.0011	CcSEcCtD
Amoxapine—Dermatitis—Docetaxel—skin cancer	0.000224	0.0011	CcSEcCtD
Amoxapine—Headache—Docetaxel—skin cancer	0.000223	0.0011	CcSEcCtD
Amoxapine—Nausea—Docetaxel—skin cancer	0.000212	0.00104	CcSEcCtD
Amoxapine—HRH4—Signaling by GPCR—NRAS—skin cancer	2.69e-05	0.000471	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—SUFU—skin cancer	2.66e-05	0.000466	CbGpPWpGaD
Amoxapine—SLC6A3—Neuronal System—HRAS—skin cancer	2.66e-05	0.000466	CbGpPWpGaD
Amoxapine—DRD2—Circadian rythm related genes—IL6—skin cancer	2.66e-05	0.000465	CbGpPWpGaD
Amoxapine—GABRA1—Neuronal System—HRAS—skin cancer	2.63e-05	0.000461	CbGpPWpGaD
Amoxapine—CHRM1—Circadian rythm related genes—IL6—skin cancer	2.6e-05	0.000455	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—FOXO4—skin cancer	2.6e-05	0.000455	CbGpPWpGaD
Amoxapine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.59e-05	0.000453	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—SHH—skin cancer	2.58e-05	0.000452	CbGpPWpGaD
Amoxapine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.58e-05	0.000452	CbGpPWpGaD
Amoxapine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.57e-05	0.000451	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—SHH—skin cancer	2.57e-05	0.00045	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—RASA1—skin cancer	2.57e-05	0.000449	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—RASA1—skin cancer	2.55e-05	0.000447	CbGpPWpGaD
Amoxapine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	2.53e-05	0.000444	CbGpPWpGaD
Amoxapine—HRH4—Signaling Pathways—BRAF—skin cancer	2.53e-05	0.000443	CbGpPWpGaD
Amoxapine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.48e-05	0.000434	CbGpPWpGaD
Amoxapine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.47e-05	0.000433	CbGpPWpGaD
Amoxapine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.46e-05	0.000431	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—FOXO4—skin cancer	2.45e-05	0.000429	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—PTCH1—skin cancer	2.45e-05	0.000429	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—SMO—skin cancer	2.45e-05	0.000429	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—PTCH1—skin cancer	2.44e-05	0.000427	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—SMO—skin cancer	2.44e-05	0.000427	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—ENO2—skin cancer	2.43e-05	0.000425	CbGpPWpGaD
Amoxapine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	2.42e-05	0.000425	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—FOXO4—skin cancer	2.42e-05	0.000423	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—PTGER4—skin cancer	2.38e-05	0.000417	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—PTGER4—skin cancer	2.37e-05	0.000415	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—CSPG4—skin cancer	2.33e-05	0.000408	CbGpPWpGaD
Amoxapine—HRH4—Signaling by GPCR—KRAS—skin cancer	2.32e-05	0.000406	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—SHH—skin cancer	2.27e-05	0.000397	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—RASA1—skin cancer	2.25e-05	0.000395	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—SHH—skin cancer	2.23e-05	0.000391	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—SHH—skin cancer	2.23e-05	0.00039	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—SHH—skin cancer	2.22e-05	0.000389	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—RASA1—skin cancer	2.22e-05	0.000388	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—RASA1—skin cancer	2.21e-05	0.000387	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—RASA1—skin cancer	2.21e-05	0.000386	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—SHH—skin cancer	2.18e-05	0.000383	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—RASA1—skin cancer	2.17e-05	0.00038	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—SMO—skin cancer	2.15e-05	0.000376	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—PTCH1—skin cancer	2.15e-05	0.000376	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PTCH1—skin cancer	2.12e-05	0.00037	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—SMO—skin cancer	2.12e-05	0.00037	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PTCH1—skin cancer	2.11e-05	0.00037	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—SMO—skin cancer	2.11e-05	0.00037	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—FOXO4—skin cancer	2.11e-05	0.000369	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PTCH1—skin cancer	2.1e-05	0.000368	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—SMO—skin cancer	2.1e-05	0.000368	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—FOXO4—skin cancer	2.09e-05	0.000367	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—PTGER4—skin cancer	2.09e-05	0.000366	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—SMO—skin cancer	2.07e-05	0.000363	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PTCH1—skin cancer	2.07e-05	0.000363	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—PTGER4—skin cancer	2.06e-05	0.000361	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—PTGER4—skin cancer	2.05e-05	0.00036	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—PTGER4—skin cancer	2.05e-05	0.000359	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—SHH—skin cancer	2.03e-05	0.000355	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—RASA1—skin cancer	2.02e-05	0.000353	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—PTGER4—skin cancer	2.02e-05	0.000353	CbGpPWpGaD
Amoxapine—HRH4—Signaling by GPCR—HRAS—skin cancer	1.97e-05	0.000345	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—SMO—skin cancer	1.92e-05	0.000337	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PTCH1—skin cancer	1.92e-05	0.000337	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—TERT—skin cancer	1.9e-05	0.000333	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—TERT—skin cancer	1.9e-05	0.000332	CbGpPWpGaD
Amoxapine—HRH4—Signaling by GPCR—IL6—skin cancer	1.88e-05	0.00033	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—PTGER4—skin cancer	1.87e-05	0.000328	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—FOXO4—skin cancer	1.85e-05	0.000324	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—TERT—skin cancer	1.85e-05	0.000323	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—FOXO4—skin cancer	1.82e-05	0.000319	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—TERT—skin cancer	1.82e-05	0.000318	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—FOXO4—skin cancer	1.81e-05	0.000318	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—FOXO4—skin cancer	1.81e-05	0.000317	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—FOXO4—skin cancer	1.78e-05	0.000312	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—TERT—skin cancer	1.73e-05	0.000304	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—FOXO4—skin cancer	1.65e-05	0.00029	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—TERT—skin cancer	1.64e-05	0.000286	CbGpPWpGaD
Amoxapine—ADRA2A—Hemostasis—NRAS—skin cancer	1.62e-05	0.000284	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—TERT—skin cancer	1.61e-05	0.000283	CbGpPWpGaD
Amoxapine—HTR6—Signaling by GPCR—NRAS—skin cancer	1.6e-05	0.00028	CbGpPWpGaD
Amoxapine—HTR7—Signaling by GPCR—NRAS—skin cancer	1.6e-05	0.00028	CbGpPWpGaD
Amoxapine—HRH4—Signaling Pathways—NRAS—skin cancer	1.59e-05	0.000278	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—ENO2—skin cancer	1.58e-05	0.000277	CbGpPWpGaD
Amoxapine—HTR1B—Signaling by GPCR—NRAS—skin cancer	1.56e-05	0.000272	CbGpPWpGaD
Amoxapine—DRD4—Signaling by GPCR—NRAS—skin cancer	1.53e-05	0.000268	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—BRAF—skin cancer	1.5e-05	0.000263	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—BRAF—skin cancer	1.5e-05	0.000263	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—BRAF—skin cancer	1.46e-05	0.000256	CbGpPWpGaD
Amoxapine—HTR2B—Signaling by GPCR—NRAS—skin cancer	1.46e-05	0.000256	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—BRAF—skin cancer	1.44e-05	0.000252	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—ERCC2—skin cancer	1.41e-05	0.000247	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—TERT—skin cancer	1.41e-05	0.000246	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—TERT—skin cancer	1.4e-05	0.000245	CbGpPWpGaD
Amoxapine—ADRA2A—Hemostasis—KRAS—skin cancer	1.4e-05	0.000245	CbGpPWpGaD
Amoxapine—DRD1—Signaling by GPCR—NRAS—skin cancer	1.38e-05	0.000241	CbGpPWpGaD
Amoxapine—HTR6—Signaling by GPCR—KRAS—skin cancer	1.38e-05	0.000241	CbGpPWpGaD
Amoxapine—HTR7—Signaling by GPCR—KRAS—skin cancer	1.38e-05	0.000241	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—BRAF—skin cancer	1.37e-05	0.000241	CbGpPWpGaD
Amoxapine—HRH4—Signaling Pathways—KRAS—skin cancer	1.37e-05	0.00024	CbGpPWpGaD
Amoxapine—DRD3—Signaling by GPCR—NRAS—skin cancer	1.36e-05	0.000238	CbGpPWpGaD
Amoxapine—HTR1B—Signaling by GPCR—KRAS—skin cancer	1.34e-05	0.000234	CbGpPWpGaD
Amoxapine—DRD4—Signaling by GPCR—KRAS—skin cancer	1.32e-05	0.000231	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—BRAF—skin cancer	1.29e-05	0.000227	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—BRAF—skin cancer	1.28e-05	0.000224	CbGpPWpGaD
Amoxapine—HTR2B—Signaling by GPCR—KRAS—skin cancer	1.26e-05	0.00022	CbGpPWpGaD
Amoxapine—ADRA2A—Hemostasis—TP53—skin cancer	1.24e-05	0.000217	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—TERT—skin cancer	1.23e-05	0.000216	CbGpPWpGaD
Amoxapine—HRH4—Signaling Pathways—TP53—skin cancer	1.22e-05	0.000213	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—TERT—skin cancer	1.21e-05	0.000213	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—TERT—skin cancer	1.21e-05	0.000212	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—TERT—skin cancer	1.21e-05	0.000212	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—TERT—skin cancer	1.19e-05	0.000208	CbGpPWpGaD
Amoxapine—ADRA2A—Hemostasis—HRAS—skin cancer	1.19e-05	0.000208	CbGpPWpGaD
Amoxapine—DRD1—Signaling by GPCR—KRAS—skin cancer	1.19e-05	0.000208	CbGpPWpGaD
Amoxapine—HTR1A—Signaling by GPCR—NRAS—skin cancer	1.18e-05	0.000207	CbGpPWpGaD
Amoxapine—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.18e-05	0.000206	CbGpPWpGaD
Amoxapine—HTR6—Signaling by GPCR—HRAS—skin cancer	1.17e-05	0.000205	CbGpPWpGaD
Amoxapine—DRD3—Signaling by GPCR—KRAS—skin cancer	1.17e-05	0.000205	CbGpPWpGaD
Amoxapine—HTR7—Signaling by GPCR—HRAS—skin cancer	1.17e-05	0.000205	CbGpPWpGaD
Amoxapine—HRH4—Signaling Pathways—HRAS—skin cancer	1.16e-05	0.000204	CbGpPWpGaD
Amoxapine—HTR1B—Signaling by GPCR—HRAS—skin cancer	1.14e-05	0.000199	CbGpPWpGaD
Amoxapine—HTR6—Signaling by GPCR—IL6—skin cancer	1.12e-05	0.000196	CbGpPWpGaD
Amoxapine—DRD4—Signaling by GPCR—HRAS—skin cancer	1.12e-05	0.000196	CbGpPWpGaD
Amoxapine—HTR7—Signaling by GPCR—IL6—skin cancer	1.12e-05	0.000196	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—BRAF—skin cancer	1.11e-05	0.000195	CbGpPWpGaD
Amoxapine—HRH4—Signaling Pathways—IL6—skin cancer	1.11e-05	0.000195	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—BRAF—skin cancer	1.11e-05	0.000194	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—TERT—skin cancer	1.11e-05	0.000194	CbGpPWpGaD
Amoxapine—HTR1B—Signaling by GPCR—IL6—skin cancer	1.09e-05	0.000191	CbGpPWpGaD
Amoxapine—DRD4—Signaling by GPCR—IL6—skin cancer	1.07e-05	0.000188	CbGpPWpGaD
Amoxapine—HTR2B—Signaling by GPCR—HRAS—skin cancer	1.07e-05	0.000187	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—NRAS—skin cancer	1.04e-05	0.000182	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.02e-05	0.000179	CbGpPWpGaD
Amoxapine—HTR2B—Signaling by GPCR—IL6—skin cancer	1.02e-05	0.000179	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—NRAS—skin cancer	1.02e-05	0.000179	CbGpPWpGaD
Amoxapine—HTR1A—Signaling by GPCR—KRAS—skin cancer	1.02e-05	0.000179	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—NRAS—skin cancer	1.02e-05	0.000178	CbGpPWpGaD
Amoxapine—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.01e-05	0.000178	CbGpPWpGaD
Amoxapine—DRD1—Signaling by GPCR—HRAS—skin cancer	1.01e-05	0.000177	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—NRAS—skin cancer	1e-05	0.000176	CbGpPWpGaD
Amoxapine—DRD3—Signaling by GPCR—HRAS—skin cancer	9.94e-06	0.000174	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—BRAF—skin cancer	9.78e-06	0.000171	CbGpPWpGaD
Amoxapine—DRD1—Signaling by GPCR—IL6—skin cancer	9.65e-06	0.000169	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—BRAF—skin cancer	9.62e-06	0.000168	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—BRAF—skin cancer	9.6e-06	0.000168	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—BRAF—skin cancer	9.57e-06	0.000168	CbGpPWpGaD
Amoxapine—DRD3—Signaling by GPCR—IL6—skin cancer	9.52e-06	0.000167	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—NRAS—skin cancer	9.45e-06	0.000166	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—NRAS—skin cancer	9.44e-06	0.000165	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—BRAF—skin cancer	9.42e-06	0.000165	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—NRAS—skin cancer	9.31e-06	0.000163	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—ERCC2—skin cancer	9.19e-06	0.000161	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—NRAS—skin cancer	9.19e-06	0.000161	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—NRAS—skin cancer	9.04e-06	0.000158	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—KRAS—skin cancer	8.95e-06	0.000157	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—KRAS—skin cancer	8.81e-06	0.000154	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—KRAS—skin cancer	8.79e-06	0.000154	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—KRAS—skin cancer	8.76e-06	0.000153	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—BRAF—skin cancer	8.75e-06	0.000153	CbGpPWpGaD
Amoxapine—HTR1A—Signaling by GPCR—HRAS—skin cancer	8.67e-06	0.000152	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—NRAS—skin cancer	8.63e-06	0.000151	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—KRAS—skin cancer	8.63e-06	0.000151	CbGpPWpGaD
Amoxapine—HTR2C—Signaling by GPCR—HRAS—skin cancer	8.62e-06	0.000151	CbGpPWpGaD
Amoxapine—ADRA2A—Metabolism—PTGS2—skin cancer	8.45e-06	0.000148	CbGpPWpGaD
Amoxapine—HTR1A—Signaling by GPCR—IL6—skin cancer	8.3e-06	0.000145	CbGpPWpGaD
Amoxapine—HTR2C—Signaling by GPCR—IL6—skin cancer	8.25e-06	0.000145	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—NRAS—skin cancer	8.14e-06	0.000143	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—KRAS—skin cancer	8.14e-06	0.000143	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—KRAS—skin cancer	8.13e-06	0.000142	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—NRAS—skin cancer	8.03e-06	0.000141	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—KRAS—skin cancer	8.01e-06	0.00014	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—KRAS—skin cancer	7.91e-06	0.000138	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—KRAS—skin cancer	7.78e-06	0.000136	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—HRAS—skin cancer	7.61e-06	0.000133	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—HRAS—skin cancer	7.49e-06	0.000131	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—HRAS—skin cancer	7.47e-06	0.000131	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—HRAS—skin cancer	7.45e-06	0.00013	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—KRAS—skin cancer	7.43e-06	0.00013	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—HRAS—skin cancer	7.33e-06	0.000128	CbGpPWpGaD
Amoxapine—DRD2—Signaling by GPCR—IL6—skin cancer	7.28e-06	0.000128	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—TP53—skin cancer	7.23e-06	0.000127	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—TP53—skin cancer	7.22e-06	0.000127	CbGpPWpGaD
Amoxapine—HTR2A—Signaling by GPCR—IL6—skin cancer	7.17e-06	0.000126	CbGpPWpGaD
Amoxapine—HRH1—Signaling by GPCR—IL6—skin cancer	7.15e-06	0.000125	CbGpPWpGaD
Amoxapine—CHRM1—Signaling by GPCR—IL6—skin cancer	7.13e-06	0.000125	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—TP53—skin cancer	7.03e-06	0.000123	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling by GPCR—IL6—skin cancer	7.02e-06	0.000123	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—KRAS—skin cancer	7e-06	0.000123	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—NRAS—skin cancer	7e-06	0.000123	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—NRAS—skin cancer	6.96e-06	0.000122	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—HRAS—skin cancer	6.92e-06	0.000121	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—TP53—skin cancer	6.92e-06	0.000121	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—KRAS—skin cancer	6.91e-06	0.000121	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—HRAS—skin cancer	6.91e-06	0.000121	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—HRAS—skin cancer	6.81e-06	0.000119	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—HRAS—skin cancer	6.72e-06	0.000118	CbGpPWpGaD
Amoxapine—HTR6—Signaling Pathways—IL6—skin cancer	6.62e-06	0.000116	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—HRAS—skin cancer	6.61e-06	0.000116	CbGpPWpGaD
Amoxapine—HTR7—Signaling Pathways—IL6—skin cancer	6.61e-06	0.000116	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—TP53—skin cancer	6.6e-06	0.000116	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling by GPCR—IL6—skin cancer	6.52e-06	0.000114	CbGpPWpGaD
Amoxapine—HTR1B—Signaling Pathways—IL6—skin cancer	6.43e-06	0.000113	CbGpPWpGaD
Amoxapine—DRD4—Signaling Pathways—IL6—skin cancer	6.33e-06	0.000111	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—HRAS—skin cancer	6.31e-06	0.000111	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—TP53—skin cancer	6.23e-06	0.000109	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—NRAS—skin cancer	6.14e-06	0.000108	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—TP53—skin cancer	6.14e-06	0.000108	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—NRAS—skin cancer	6.05e-06	0.000106	CbGpPWpGaD
Amoxapine—HTR2B—Signaling Pathways—IL6—skin cancer	6.04e-06	0.000106	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—NRAS—skin cancer	6.03e-06	0.000106	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—KRAS—skin cancer	6.02e-06	0.000105	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—NRAS—skin cancer	6.01e-06	0.000105	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—KRAS—skin cancer	5.99e-06	0.000105	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—HRAS—skin cancer	5.95e-06	0.000104	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—NRAS—skin cancer	5.92e-06	0.000104	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—HRAS—skin cancer	5.87e-06	0.000103	CbGpPWpGaD
Amoxapine—DRD1—Signaling Pathways—IL6—skin cancer	5.7e-06	9.98e-05	CbGpPWpGaD
Amoxapine—DRD3—Signaling Pathways—IL6—skin cancer	5.62e-06	9.85e-05	CbGpPWpGaD
Amoxapine—CYP2D6—Metabolism—PTGS2—skin cancer	5.51e-06	9.65e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—NRAS—skin cancer	5.5e-06	9.63e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—TP53—skin cancer	5.35e-06	9.38e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—TP53—skin cancer	5.33e-06	9.33e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—KRAS—skin cancer	5.29e-06	9.26e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—KRAS—skin cancer	5.2e-06	9.11e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—KRAS—skin cancer	5.19e-06	9.09e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—KRAS—skin cancer	5.18e-06	9.07e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—HRAS—skin cancer	5.12e-06	8.97e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—KRAS—skin cancer	5.1e-06	8.92e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—HRAS—skin cancer	5.09e-06	8.92e-05	CbGpPWpGaD
Amoxapine—HTR1A—Signaling Pathways—IL6—skin cancer	4.9e-06	8.58e-05	CbGpPWpGaD
Amoxapine—HTR2C—Signaling Pathways—IL6—skin cancer	4.88e-06	8.54e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—KRAS—skin cancer	4.73e-06	8.29e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—TP53—skin cancer	4.7e-06	8.23e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—TP53—skin cancer	4.62e-06	8.1e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—TP53—skin cancer	4.61e-06	8.08e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—TP53—skin cancer	4.6e-06	8.06e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—TP53—skin cancer	4.53e-06	7.93e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—HRAS—skin cancer	4.5e-06	7.87e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—HRAS—skin cancer	4.42e-06	7.75e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—HRAS—skin cancer	4.41e-06	7.73e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—HRAS—skin cancer	4.4e-06	7.71e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—HRAS—skin cancer	4.33e-06	7.59e-05	CbGpPWpGaD
Amoxapine—DRD2—Signaling Pathways—IL6—skin cancer	4.3e-06	7.54e-05	CbGpPWpGaD
Amoxapine—HTR2A—Signaling Pathways—IL6—skin cancer	4.23e-06	7.41e-05	CbGpPWpGaD
Amoxapine—HRH1—Signaling Pathways—IL6—skin cancer	4.22e-06	7.4e-05	CbGpPWpGaD
Amoxapine—CHRM1—Signaling Pathways—IL6—skin cancer	4.21e-06	7.37e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—TP53—skin cancer	4.21e-06	7.37e-05	CbGpPWpGaD
Amoxapine—ADRA1A—Signaling Pathways—IL6—skin cancer	4.15e-06	7.26e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—HRAS—skin cancer	4.02e-06	7.05e-05	CbGpPWpGaD
Amoxapine—ADRA2A—Signaling Pathways—IL6—skin cancer	3.85e-06	6.75e-05	CbGpPWpGaD
